Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in the United States

被引:128
|
作者
Rosenblum, Andrew [1 ]
Cleland, CharlesM. [1 ,2 ]
Fong, Chunki [1 ]
Kayman, Deborah J. [1 ]
Tempalski, Barbara [1 ]
Parrino, Andmark [3 ]
机构
[1] Natl Dev & Res Inst Inc NDRI, 71 W 23 St,8th Floor, New York, NY 10010 USA
[2] NYU, Coll Nursing, New York, NY 10003 USA
[3] AATOD, New York, NY 10014 USA
关键词
D O I
10.1155/2011/948789
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This study examined commuting patterns among 23,141 methadone patients enrolling in 84 opioid treatment programs (OTPs) in the United States. Patients completed an anonymous one-page survey. A linear mixed model analysis was used to predict distance traveled to the OTP. More than half (60%) the patients traveled < 10 miles and 6% travelled between 50 and 200 miles to attend an OTP; 8% travelled across a state border to attend an OTP. In the multivariate model (n = 17, 792), factors significantly (P < .05) associated with distance were, residing in the Southeast or Midwest, low urbanicity, area of the patient's ZIP code, younger age, non-Hispanic white race/ethnicity, prescription opioid abuse, and no heroin use. A significant number of OTP patients travel considerable distances to access treatment. To reduce obstacles to OTP access, policy makers and treatment providers should be alert to patients' commuting patterns and to factors associated with them.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Treatment utilization among persons with opioid use disorder in the United States
    Wu, Li-Tzy
    Zhu, He
    Swartz, Marvin S.
    DRUG AND ALCOHOL DEPENDENCE, 2016, 169 : 117 - 127
  • [42] Opioid use disorder in the United States: Insurance status and treatment access
    Becker, W. C.
    Fiellin, D. A.
    Merrill, J. O.
    Schulman, B.
    Finkelstein, R.
    Olsen, Y.
    Busch, S. H.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 : 68 - 68
  • [43] Treatment for Opioid Use Disorder: Population Estimates - United States, 2022
    Dowell, Deborah
    Brown, Samantha
    Gyawali, Shiromani
    Hoenig, Jennifer
    Ko, Jean
    Mikosz, Christina
    Ussery, Emily
    Baldwin, Grant
    Jones, Christopher M.
    Olsen, Yngvild
    Tomoyasu, Naomi
    Han, Beth
    Compton, Wilson M.
    Volkow, Nora D.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2024, 73 (25): : 567 - 574
  • [44] The role of age and opioid agonist treatment on substance use treatment completion in the United States
    Clark, Carissa van den Berk
    Pickard, Joseph G.
    Drallmeier, Theresa
    AGING & MENTAL HEALTH, 2022, 26 (06) : 1295 - 1302
  • [45] Status of Backflow Prevention and Cross-Connection Control Programs in the United States
    LeBas, Mitchell J.
    Stewart, Carolyn
    Garner, Steven
    Hardin, Byron
    JOURNAL AMERICAN WATER WORKS ASSOCIATION, 2018, 110 (02): : 48 - 53
  • [46] COLLEGIATE ALCOHOL DRUG-TREATMENT PROGRAMS IN THE UNITED-STATES
    DEAN, JC
    DEAN, HE
    KLEINER, DL
    INTERNATIONAL JOURNAL OF THE ADDICTIONS, 1987, 22 (08): : 767 - 778
  • [47] Characterizing variability in state-level regulations governing opioid treatment programs
    Jackson, Joanna R.
    Harle, Christopher A.
    Silverman, Ross D.
    Simon, Kosali
    Menachemi, Nir
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 115
  • [48] Availability of Outpatient Substance Use Disorder Treatment Programs in the United States
    Perron, Brian E.
    Gillespie, David F.
    Alexander-Eitzman, Ben
    Delva, Jorge
    SUBSTANCE USE & MISUSE, 2010, 45 (7-8) : 1097 - 1111
  • [49] Access to Medications for Opioid Use Disorder for Persons With Human Immunodeficiency Virus in the United States: Gaps in Coverage by State AIDS Drug Assistance Programs
    McManus, Kathleen A.
    Davy-Mendez, Thibaut
    Killelea, Amy
    Schranz, Asher J.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (04):
  • [50] The Impact of CDC's Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States
    Dong, Huiru
    Stringfellow, Erin
    Jalali, Mohammad
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260